Mrs. Christine Lynn Ward is a pharmacist who is specialized in Pharmacotherapy in Bellingham, Washington. Patients can reach her at 2901 Squalicum Pkwy, Bellingham or contact her on 360-734-5400. Active license number of Mrs. Christine Lynn Ward is PH00018329 for Pharmacotherapy in Washington. Mrs. Christine Lynn Ward is a licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing pharmacotherapeutic care of patients, by developing, implementing, monitoring, and modifying complex treatment plans, providing advanced level education and consultation, and collaborating with other health professionals in the management of therapy.
Complete Profile:
Mrs. Christine Lynn Ward speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mrs. Christine Lynn Ward are as mentioned below.
NPI Number:
1326221250
NPI Enumeration Date:
13 Dec, 2007
NPI Last Update On:
13 Dec, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mrs. Christine Lynn Ward are as mentioned below.
Specialization
License Number
State
Status
Pharmacotherapy
PH00018329
Washington
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
2901 Squalicum Pkwy, Bellingham, Washington
Zip:
98225-1851
Phone Number:
360-734-5400
Fax Number:
--
Patients can reach Mrs. Christine Lynn Ward at 2901 Squalicum Pkwy, Bellingham, Washington or can call on phone at 360-734-5400.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.